← Leaderboards
Glenn Larsen
Aquinnah Pharmaceuticals, Inc.
$5,246,432
Attributed
$10,492,863
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,492,863 · 5
By mechanism
R44$9,431,105 · 3
R43$1,061,758 · 2
Top collaborators
- Benjamin L Wolozin10 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsNeurodegenerative DisordersSmall MoleculePharmacologic SubstanceLeadNovel Therapeutic InterventionEffective TherapyDrug DevelopmentLinkIn VivoAnimal ModelUniversitiesMutationPathologySmall Business Innovation Research GrantBostonDoseDrug CandidateCellsDisease ProgressionIn VitroBrainLaboratories
Grant awards (10)
Development of a novel oral brain penetrant therapeutic for ALS disease$1,499,212
R44 · FY2025 · NS · contact PI
Development of a novel Alzheimer's disease therapeutic targeting tau$998,691
R44 · FY2025 · AG · contact PI
Development of a novel Alzheimer's disease therapeutic targeting tau$999,721
R44 · FY2024 · AG · contact PI
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,022,579
R44 · FY2021 · AG · contact PI
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,475,961
R44 · FY2020 · AG · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$2,510,981
R44 · FY2019 · NS · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$923,960
R44 · FY2018 · NS · contact PI
Tau/TIA1 aggregation inhibitors for the treatment of AD$379,465
R43 · FY2018 · AG · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$182,737
R43 · FY2016 · NS · contact PI
TDP-43 aggregation inhibitors for the treatment of ALS$499,556
R43 · FY2015 · NS · contact PI